At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Approved Non-small Cell Lung Cancer (NSCLC) therapies (drug)
- How long the study runs
- Study runs about 11 months (dates as stated)
- About the drug or intervention
- Approved Non-small Cell Lung Cancer (NSCLC) therapies — drug: As prescribed by treating physician
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 650
- Started
- 2024-11-25
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for non-small cell lung cancer (nsclc)
- • Clinical study - 650 participants
- • The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with non-small cell lung cancer (nsclc)
Where?
- • London - Evidera
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Non-small Cell Lung Cancer (NSCLC)
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patients
- ✓Aged ≥18 years at the time of enrollment in the study
- ✓Resident of the US, Germany, or Japan
- ✓Able to read, speak, and understand English, German or Japanese
- ✓Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
Who cannot take part
- ✗Patients
- ✗Being diagnosed with another cancer alongside NSCLC
- ✗Not willing to be audio-recorded during the interview
- ✗Physicians
See the full criteria
Inclusion Criteria:
Patients
* Aged ≥18 years at the time of enrollment in the study
* Resident of the US, Germany, or Japan
* Able to read, speak, and understand English, German or Japanese
* Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
Physicians
* Resident of the US, Germany, or Japan
* Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
* Treated at least three new patients with resectable NSCLC in the past year
Exclusion Criteria:
Patients
* Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
* Being diagnosed with another malignancy alongside NSCLC
* Not willing to be audio-recorded during the interview
Physicians
* Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
* Not willing to be audio-recorded during the interview
Where Is This Study? (1 UK site)
Evidera
London, United Kingdom
Data sourced from ClinicalTrials.gov · Last verified: 2026-07